NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017.

Cover of GeneReviews®

GeneReviews® [Internet].

Show details

Hereditary Folate Malabsorption

Synonym: Congenital Folate Malabsorption

, MD and , MD.

Author Information

Initial Posting: ; Last Update: April 27, 2017.

Summary

Clinical characteristics.

Hereditary folate malabsorption (HFM) is characterized by folate deficiency with impaired intestinal folate absorption and impaired folate transport into the central nervous system. Findings include poor feeding, failure to thrive, and anemia. There can be leukopenia and thrombocytopenia, diarrhea and/or oral mucositis, hypoimmunoglobulinemia, and other immunologic dysfunction resulting in infections, most often Pneumocystis jerovicii pneumonia. Neurologic manifestations include developmental delays, cognitive and motor impairment, behavioral disorders and, frequently, seizures.

Diagnosis/testing.

The diagnosis of HFM is established in a proband: with anemia, impaired absorption of an oral folate load, and low cerebrospinal fluid (CSF) folate concentration (even after correction of the serum folate concentration); and/or by the identification of biallelic pathogenic variants in SLC46A1 on molecular genetic testing.

Management.

Treatment of manifestations: Parenteral (intramuscular) or high-dose oral 5-formyltetrahydrofolate (5-formylTHF, folinic acid, Leucovorin®) or the active isomer of 5-formylTHF (Isovorin® or Fusilev®) can obviate the signs and symptoms of HFM. Dosing is aimed at achieving CSF folate trough concentrations as close as possible to the normal range for the age of the affected individual (infants and children have higher CSF folate levels than adults).

Prevention of primary manifestations: Early treatment readily corrects the systemic folate deficiency and can achieve sufficient CSF folate levels to prevent the neurologic consequences of HFM.

Prevention of secondary complications: In affected individuals with selective IgA deficiency, appropriate precautions for blood product transfusion should be taken.

Surveillance: To assess adequacy of treatment, surveillance should include: periodic complete blood counts; measurements of serum and CSF folate concentrations; measurements of serum and CSF homocysteine concentrations; and monitoring of the affected individual’s neurologic status. Serial measurement of immunoglobulins is not necessary once the levels return to the normal range and serum folate and hemoglobin levels remain normal and stable.

Agents/circumstances to avoid: If possible, folic acid should not be used for the treatment of HFM because it binds very tightly to the folate receptor. This may impair transport of physiologic folates across the choroid plexus.

Evaluation of relatives at risk: For at-risk sibs, molecular genetic testing when the family-specific pathogenic variants are known; otherwise, assessment of blood and CSF folate levels and, if warranted, intestinal absorption of folate immediately after birth, or as soon as the diagnosis is confirmed in the proband.

Pregnancy management: Affected women should increase their folate intake above the maintenance dose prior to attempting to conceive; infants with HFM do not appear to be at an increased risk for neural malformations typically associated with maternal folate deficiency during pregnancy.

Genetic counseling.

HFM is inherited in an autosomal recessive manner. Heterozygotes (carriers) are asymptomatic and do not have clinical signs of folate deficiency. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. If both pathogenic variants have been identified in the family, carrier testing for at-risk relatives, prenatal diagnosis for a pregnancy at increased risk, and preimplantation genetic diagnosis for HFM are possible.

Diagnosis

Hereditary folate malabsorption (HFM) is characterized by folate deficiency with impaired intestinal folate absorption and impaired folate transport into the central nervous system [Geller et al 2002, Zhao et al 2009, Zhao et al 2014, Zhao et al 2017].

Suggestive Findings

Hereditary folate malabsorption (HFM) should be suspected in infants with the following clinical, family history, supportive laboratory, and bone marrow biopsy findings:

Clinical features

  • Anorexia with poor weight gain and failure to thrive
  • Diarrhea and/or oral mucositis
  • Infections with unusual organisms (typically pneumonia caused by Pneumocystis jirovecii) associated with hypoimmunoglobulinemia
  • Neurologic manifestations including developmental delays, cognitive and behavioral disorders, motor impairment, ataxia, and, frequently, seizures

Family history

  • History of sib deaths in early infancy as a result of infection, anemia, and/or a seizure disorder
  • Pedigree analysis consistent with autosomal recessive inheritance

Note: Lack of a family history of other individuals with clinical features of HFM does not preclude the diagnosis.

Supportive laboratory findings

  • Complete blood count
    • Anemia, typically with macrocytic red cell indices and macrocytosis and neutrophil hypersegmentation on peripheral smear, associated with low serum folate
      Note: Normocytic anemia can be seen when there is accompanying poor nutrition and/or iron deficiency.
    • In some cases, leukopenia and/or thrombocytopenia – the latter typically mild to moderate but sometimes severe
  • Quantitative serum immunoglobulin levels. Low concentrations of IgG, IgM, and IgA [Zhao et al 2007, Borzutzky et al 2009, Kishimoto et al 2014, Erlacher et al 2015, Zhao et al 2017]
  • Erythrocyte and serum folate concentrations
  • Cerebrospinal fluid (CSF) folate concentration
    • Low CSF folate concentration even after correction of the serum folate concentration:
      • Baseline CSF folate concentrations in untreated affected individuals range from 0 to 1.5 nmol/L.
      • Normal CSF folate levels are higher in infancy and through adolescence (see Treatment of Manifestations).
      • In unaffected adults, CSF levels are 2-3 times the normal serum folate concentration or ≥10-45 nmol/L). The levels are much higher in infants and young children.
    • Following intramuscular administration of 5 mg of 5-formyltetrahydrofolate (5-formylTHF or Leucovorin®), the CSF folate concentration peaks transiently at one to two hours and returns to the baseline value within approximately 24 hours. However, the CSF folate concentration remains below the serum folate concentration in individuals with HFM, a finding consistent with impaired folate transport across the blood:choroid plexus:CSF barrier [Poncz et al 1981, Corbeel et al 1985, Malatack et al 1999, Zhao et al 2017].

Bone marrow biopsy

  • Evidence of megaloblastic anemia with exclusion of other causes of anemia
  • Dyserythropoesis variably found

Establishing the Diagnosis

The diagnosis of HFM is established in a proband:

  • With anemia, impaired absorption of an oral folate load, and low cerebrospinal fluid (CSF) folate concentration (even after correction of the serum folate concentration); AND/OR
  • By the identification of biallelic pathogenic variants in SLC46A1 on molecular genetic testing (see Table 1).

Molecular genetic testing approaches can include single-gene testing or use of a multi-gene panel:

  • Single-gene testing. Sequence analysis of SLC46A1 is performed first and followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found.
  • A multi-gene panel that includes SLC46A1 and other genes of interest (see Differential Diagnosis) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this GeneReview; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.
    For more information on multi-gene panels click here.

Table 1.

Molecular Genetic Testing Used in Hereditary Folate Malabsorption

Gene 1Test MethodProportion of Probands with Pathogenic Variants 2 Detectable by This Method
SLC46A1Sequence analysis 3100% 4, 5, 6
1.
2.

See Molecular Genetics for information on allelic variants detected in this gene.

3.

Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.

4.
5.

There is a common pathogenic variant among individuals of Puerto Rican heritage: c.1082-1G>A.

6.

One variant was a deep intron 3 single-nucleotide variant that generated a cryptic splice donor site resulting in a 168-bp insertion [Kishimoto et al 2014]. Sequencing methodologies that can detect such variants should be considered.

Clinical Characteristics

Clinical Description

Hereditary folate malabsorption (HFM) is characterized by (1) impaired intestinal absorption of folates causing systemic folate deficiency and (2) impaired transport of folates across the blood:choroid plexus:CSF barrier, resulting in central nervous system folate deficiency. Infants with HFM may be born with adequate stores of folate but subsequently are unable to absorb folate from breast milk or formula and thus become folate deficient. Low serum and CSF folate concentrations were documented prior to the onset of clinical signs in a one-month old whose older sib was affected. Clinical manifestations of folate deficiency have been reported as early as age two months. The age at which signs of folate deficiency appear in an infant depends at least in part on the level of folate stores accumulated in utero.

Anemia. Folate deficiency results primarily in megaloblastic anemia but may affect all three hematopoietic lineages. The anemia may be severe and require transfusion, although with rapid diagnosis and folate repletion, transfusion should not be necessary. The anemia begins to correct within a few days after parenteral administration of folate (see Treatment of Manifestations).

Immunodeficiency. Immunologic deficiency, which may include profound humoral and cellular immodeficiency that mimics severe combined immune deficiency, may accompany the initial manifestations of HFM. Infants with HFM and recurrent infections may die in early infancy, prior to diagnosis.

Leukopenia can be a consequence of untreated severe folate deficiency [Malatack et al 1999, Takeda et al 2002, Zhao et al 2007, Borzutzky et al 2009].

Hypoimmunoglobulinemia not associated with lymphopenia can result in infections with Pneumocystis jiroveccii (pneumonia), C. difficile, and cytomegalovirus in affected infants and/or their sibs, who may die in early infancy prior to diagnosis [Malatack et al 1999, Geller et al 2002, Sofer et al 2007, Zhao et al 2007, Shin et al 2011, Kishimoto et al 2014, Erlacher et al 2015]. In one individual, absent antibody responses and lack of mitogen-induced lymphocyte proliferation occurred in conjunction with hypogammaglobulinemia; with adequate treatment, low serum IgA levels persisted while other immunologic parameters normalized [Borzutzky et al 2009].

Neurologic signs. In some individuals with HFM, neurologic signs are part of the initial manifestations, whereas in most others, they develop later in the disease course. Neurologic features include developmental delays, cognitive and motor impairment, behavioral abnormalities, ataxia and other movement disorders, peripheral neuropathy, and seizures. It is unclear why some individuals do not have neurologic signs, as all affected individuals have very low CSF folate concentrations [Su 1976, Corbeel et al 1985, Urbach et al 1987, Steinschneider et al 1990, Malatack et al 1999, Geller et al 2002, Sofer et al 2007, Zhao et al 2007, Meyer et al 2010, Shin et al 2011, Zhao et al 2017].

X-ray, CT, or MRI of the head. Intracranial calcifications have been reported in individuals with HFM [Lanzkowsky et al 1969, Corbeel et al 1985, Jebnoun et al 2001, Ahmad et al 2015, Wang et al 2015]. Note: Neural calcifications are also a common finding in children treated with methotrexate [McIntosh et al 1977].

Genotype-Phenotype Correlations

Because of the rarity of HFM, genotype-phenotype correlations have not as yet been established. Anecdotally, a benign clinical phenotype was seen in an individual (now age 36) with homozygous pathogenic SLC46A1 variants resulting in the complete absence of the PCFT protein, who was treated early in infancy with parenteral 5-formylTHF (see Pregnancy Management).

Prevalence

A clinical diagnosis of HFM has been reported in at least one person in 38 families to date. Of these, the diagnosis was confirmed by molecular genetic testing in 31 families [Zhao et al 2017].

The prevalence of this disorder is likely to be much greater than reflected in clinical reports to date, as infants with HFM may die undiagnosed in early infancy. This may be particularly prevalent in underdeveloped, medically underserved countries in which consanguinity is common.

HFM is pan ethnic. The carrier frequency for HFM is unknown. Three carriers of the common Puerto Rican c.1082-1G>A pathogenic variant were detected in a random screen of 1582 newborns in selected provinces in Puerto Rico [Mahadeo et al 2011].

Differential Diagnosis

The differential diagnosis of hereditary folate malabsorption (HFM) includes the following.

Nutritional and pharmacologic

  • Vitamin B12 deficiency as a cause of megaloblastic anemia
  • Nutritional folate deficiency as a result of inadequate dietary folate
  • Intestinal disease associated with folate malabsorption
  • The use of phenytoin for the treatment of seizure disorders

Immunologic. X-linked severe combined immunodeficiency, a disorder resulting from hemizygous pathogenic variants in IL2RG

Inborn errors of metabolism

  • Glutamate formiminotransferase deficiency (OMIM 229100), an autosomal recessive disorder resulting from biallelic pathogenic variants in FTCD
  • Methionine synthase deficiency with megaloblastic anemia and developmental delays (see Disorders of Intracellular Cobalamin Metabolism)
  • Mitochondrial disorders. A variety of mitochondrial disorders, such as Kearns-Sayre syndrome, result in low CSF folate [Pérez-Dueñas et al 2011]. However, Kearns-Sayre syndrome has defining signs that distinguish it from HFM and the blood folate level in this and other mitochondrial disorders is normal. There is no evidence that these disorders are caused by a specific defect in a folate transporter. Impaired transport into the CSF may be due to the mitochondrial metabolic defects that impair energy metabolism and, secondarily, choroid plexus transport function

Folate transporter deficiency. Cerebral folate deficiency (OMIM 613068), an autosomal recessive disorder caused by biallelic pathogenic variants in FOLR1, which encodes the folate receptor-α. This condition results from impaired folate transport across the blood:choroid plexus:CSF barrier. However, individuals with cerebral folate deficiency have normal intestinal folate absorption and normal blood folate, and are not anemic. This disorder is characterized by very low CSF folate concentrations and, unlike HFM, neurologic signs typically appear several years after birth [ Steinfeld et al 2009, Grapp et al 2012, Toelle et al 2014].

Malignancy. Erythroleukemia

Management

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in a child diagnosed with hereditary folate malabsorption (HFM), the following evaluations are recommended:

  • Assessment by a pediatric neurologist to determine baseline neurologic status
  • Baseline (and follow-up) formal cognitive testing
    Note: Appropriate monitoring of neurologic/cognitive response to treatment is recommended to ensure that the CSF folate levels achieved with treatment are adequate.
  • Initial evaluation and follow up by a metabolic genetic specialist

Treatment of Manifestations

The goal of treatment is to prevent hematologic, immunologic, and neurologic deficits and to optimize the cognitive development of children with this disorder. Complete reversal of the systemic consequences of folate deficiency is easily achieved. While correction of the neurologic consequences is more difficult, favorable neurologic outcomes are possible when adequate treatment is initiated promptly.

“Folates” refers to a family of B9 vitamin compounds that are interconvertible in a series of intracellular biochemical reactions. Folate can be effective when administered by oral or parenteral routes; however, much higher oral than parenteral doses are required to correct the systemic folate deficiency. The parenteral route is probably more effective in achieving CSF folate levels appropriate to the age of the affected individual. In either case, achieving CSF folate levels in the normal range for the age of the affected individual is challenging [Torres et al 2015].

Folate Formulations

Based on the current understanding of folate transport and metabolism, the following reduced folates can be used to treat HFM:

  • 5-formyltetrahydrofolate (5-formylTHF), also known as folinic acid or Leucovorin®, is a racemic stable form of folate. The active isomer is found in low quantities in normal human tissues. Leucovorin is available in oral and parenteral formulations. There is considerable experience in dosing with this folate form (see Folate Dosing).
  • The active isomer of 5-formylTHF, (6S)5-formylTHF (also known as Isovorin® or Fusilev®), is available for parenteral administration. Anecdotal observations suggest that the active isomer may be more effective for treatment when there is refractory neurologic disease. The biologic impact of the active isomer is twice that of the racemic mixture when the dose is the same.
  • The physiologic folate predominant in blood and tissues, (6S)5-methyltetrahydrofolate or (6S)5-methylTHF, is now available commercially as Metafolin® and Deplin®. Neither drug is available for parenteral administration. Published information on the use of (6S)5-methylTHF for the treatment of HFM is not available, although the dosing should be comparable to that of (6S)5-formylTHF. The formulation of Metafolin® is too low (800 µg) to make this agent feasible for the treatment of HFM. Deplin® is available as a 15-mg tablet.

Note: If possible, folic acid should be avoided as a treatment of HFM (see Agents/Circumstances to Avoid).

Folate Dosing

Because HFM is rare, controlled studies to establish optimal treatment have not been possible. The oral dose of 5-formylTHF required to overcome the loss of PCFT-mediated intestinal folate absorption appears to vary from individual to individual. The dose required to obviate the neurologic consequences is much higher than that needed to correct the systemic folate deficiency. The dose should be guided by its effect on trough CSF folate concentrations. The end-point is CSF folate concentrations as close as possible to the normal range for the affected individual’s age:

  • The reported oral dose of 5-formylTHF associated with a “good” outcome is approximately 150-200 mg daily [Geller et al 2002]. Much higher doses have been used as well [personal communication to Author]. A reasonable starting oral dose of 5-formylTHF in an infant could be 50 mg or 10-15 mg/kg given daily as a single dose.
    Note: Normal CSF folate is approximately 100 nmol/L for infants to age two years, decreasing to approximately 75 nmol/L by age five years and to approximately 65 nmol/L by age 19 years [Verbeek et al 2008].
  • The parenteral dose required to achieve adequate blood folate levels is much lower than the oral dose. With intramuscular injections of approximately 1.0 mg/day of 5-formylTHF, the anemia will fully correct; however, the endpoint for treatment is based on the CSF folate level, which will require much higher folate doses [Torres et al 2015].

Prevention of Primary Manifestations

Infants diagnosed by genetic testing before signs and symptoms appear should be treated immediately to prevent the onset of folate deficiency and the metabolic and clinical consequences of the disorder.

Prevention of Secondary Complications

If transfusion is required, care should be taken to administer blood products that are appropriate given the immunologic status of the affected individual (e.g., washed packed red blood cells for those who have IgA-deficienciency).

Surveillance

The following should be monitored periodically to assess the adequacy of treatment, and more frequently following initial diagnosis when treatment is being optimized:

  • Complete blood count
  • Serum and CSF folate concentrations. In particular, monitoring the trough CSF folate concentration is critical to assure that the dose of folate is sufficient to achieve CSF folate concentrations as close as possible to what is normal for the affected individual’s age.
  • Neurologic/cognitive status to ensure that CSF folate levels are adequate
  • Serum and CSF homocysteine concentrations. A high homocysteine concentration is the most sensitive indicator of folate deficiency.
  • Serum immunoglobulin concentrations until they are within the normal range and the hemoglobin and serum folate levels are normal and stable

Agents/Circumstances to Avoid

If possible, folic acid should be avoided as a treatment of HFM. Although folic acid is very stable and inexpensive, and is the most common pharmacologic source of folate, it is not a physiologic folate. Folic acid binds very tightly to folate receptors, which transport the physiologic folate, 5-methylTHF, into cells by an endocytic mechanism [Kamen & Smith 2004]. Thus, folic acid may interfere with the interaction between 5-methylTHF and folate receptors required for 5-methylTHF transport across the choroid plexus into the cerebrospinal fluid [Grapp et al 2013, Zhao et al 2017].

Evaluation of Relatives at Risk

It is appropriate to evaluate apparently asymptomatic younger sibs of a proband in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.

Evaluations can include the following:

  • Molecular genetic testing if the pathogenic variants in the family are known. Molecular genetic testing of younger at-risk sibs who have not undergone prenatal testing should be performed immediately after birth. Those with biallelic SLC46A1 pathogenic variants should be treated with 5-formyltetrahydrofolate immediately.
  • If the pathogenic variants in the family are not known and genetic testing is not possible, assessment of blood and CSF folate levels and, if warranted, intestinal absorption of folate in at-risk sibs immediately after birth, or as soon as the diagnosis is confirmed in the proband

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Pregnancy Management

There is no systematic information on the outcome of pregnancy in women with HFM.

  • Although the proton-coupled folate transporter (PCFT) is highly expressed in the placenta [Qiu et al 2006], a woman with homozygous pathogenic variants in SLC46A1 that resulted in no PCFT protein production had two normal pregnancies and delivered two healthy infants. The affected woman’s parenteral 5-formylTHF dose was increased when pregnancy was planned [Poncz et al 1981; Poncz & Cohen 1996; Min et al 2008; Goldman, personal communication to Author].

Women with HFM who wish to become pregnant should increase their dose of 5-formylTHF intake above the maintenance dose well in advance of attempting to conceive. Prenatal vitamins are available containing 5-methylTHF rather than folic acid.

Of note, infants with HFM do not appear to be at an increased risk for malformations (e.g., neural tube defects) typically associated with maternal folate deficiency during pregnancy.

Therapies Under Investigation

Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

Genetic Counseling

Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. —ED.

Mode of Inheritance

Hereditary folate malabsorption (HFM) is inherited in an autosomal recessive manner.

Risk to Family Members

Parents of a proband

  • The parents of an affected child are typically obligate heterozygotes (i.e., carriers of one SLC46A1 pathogenic variant). Note: At least one fertile woman with biallelic pathogenic variants in SLC46A1 had no discernable phenotype (see Pregnancy Management).
  • Heterozygotes (carriers) are asymptomatic and do not have clinically apparent evidence of folate deficiency. It is unclear at this time whether heterozygotes may have a mild decrease in serum folate and hemoglobin.

Sibs of a proband

  • At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
  • Heterozygotes (carriers) are asymptomatic and do not have clinically apparent evidence of folate deficiency. It is unclear at this time whether heterozygotes may have a mild decrease in serum folate and hemoglobin.

Offspring of a proband. Extensive information on fertility in individuals with this disorder is not available. (See Molecular Genetics, Molecular Genetic Pathogenesis; Management, Pregnancy Management).

The offspring of an individual with HFM are obligate heterozygotes (carriers) for a pathogenic variant in SLC46A1.

Other family members. Each sib of the proband’s parents is at a 50% risk of being a carrier of an SLC46A1 pathogenic variant.

Carrier (Heterozygote) Detection

Carrier testing of at-risk relatives requires prior identification of the SLC46A1 pathogenic variants in the family.

Related Genetic Counseling Issues

See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.

Family planning

  • The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.
  • It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.

DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.

Prenatal Testing and Preimplantation Genetic Diagnosis

Once the SLC46A1 pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for HFM are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.

Resources

GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.

  • Children Living with Inherited Metabolic Diseases (CLIMB)
    United Kingdom
    Phone: 0800-652-3181
    Email: info.svcs@climb.org.uk

Molecular Genetics

Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.

Table A.

Hereditary Folate Malabsorption: Genes and Databases

Data are compiled from the following standard references: gene from HGNC; chromosome locus, locus name, critical region, complementation group from OMIM; protein from UniProt. For a description of databases (Locus Specific, HGMD) to which links are provided, click here.

Table B.

OMIM Entries for Hereditary Folate Malabsorption (View All in OMIM)

229050FOLATE MALABSORPTION, HEREDITARY
611672SOLUTE CARRIER FAMILY 46 (FOLATE TRANSPORTER), MEMBER 1; SLC46A1

Molecular Genetic Pathogenesis

SLC46A1, encoding the proton-coupled folate transporter (PCFT) protein, is a member of the superfamily of solute carriers. PCFT is highly expressed at the apical membrane of the proximal jejunum and duodenum and is required for intestinal folate absorption. PCFT and folate receptor-α are expressed in the choroid plexus, and both appear to be required for transport of folates into the CSF [Kamen et al 1991, Qiu et al 2006, Wollack et al 2008, Steinfeld et al 2009, Zhao et al 2009, Zhao et al 2011, Grapp et al 2012, Visentin et al 2014, Zhao et al 2017]. Hereditary folate malabsorption (HFM) is caused by loss-of-function variants in SLC46A1.

A Pcft-null mouse, which recapitulates the hereditary folate malabsorption syndrome, was recently generated [Salojin et al 2011]. Affected pups supplemented with folates develop normally and are fertile [personal communication to Author]. Similarly, Pcft-null mice deliver normal pups if the mother is folate sufficient [Salojin et al 2011].

Gene structure. SLC46A1 (PCFT) transcript is approximately 6.5 kb (NM_080669.5) and has five exons. This transcript variant is the longest of the 2.7 kb and 2.1 kb that have been detected [Qiu et al 2006]. For a detailed summary of gene and protein information, see Table A, Gene.

Pathogenic variants. SLC46A1 pathogenic variants reported to date are distributed in exons 1-4. A common site of mutation is in a G-C rich region of the first exon, which encodes the first extracellular loop separating the first and second transmembrane domains. SLC46A1 pathogenic variants encompass insertions, frame shifts, a stop codon, and a splice variant.

While most identified pathogenic variants have been novel (i.e., seen in only one family), the c.1082-1G>A homozygous pathogenic variant has been reported in ten apparently unrelated families of Puerto Rican ancestry [Zhao et al 2017]. This pathogenic variant, located in the splice acceptor of intron 2, causes skipping of exon 3. The protein was produced in a cell line transfected with the variant but was not detectable in the cell membrane, consistent with a trafficking defect [Qiu et al 2006].

Table 2.

SLC46A1 Pathogenic Variants Discussed in This GeneReview

DNA Nucleotide ChangePredicted Protein ChangeReference Sequences
c.439G>Cp.Gly147ArgNM_080669​.5
NP_542400​.2
c.1082-1G>Ap.Tyr362_Gly389del 1
c.1127G>Ap.Arg376Gln
c.1274C>Gp.Pro425Arg

Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff have not independently verified the classification of variants.

Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation Society (www​.hgvs.org). See Quick Reference for an explanation of nomenclature.

1.

In-frame deletion resulting from skipping of exon 3 was detected in cDNA from transformed lymphocytes of individuals with HFM [Qiu et al 2006]; the resulting transcript variant is BC01069​.1. The same pathogenic variant has now been identified in a total of ten unrelated families of Puerto Rican ancestry [Qiu et al 2006, Borzutzky et al 2009, Mahadeo et al 2011, Zhao et al 2017].

Normal gene product. The proton-coupled folate transporter (PCFT) is predicted to have 459 amino acids with a MW of approximately 50 kd. Hydropathy analysis predicted a protein with twelve transmembrane domains [ Qiu et al 2006, Nakai et al 2007, Qiu et al 2007]. This secondary structure has now been confirmed by the substituted cysteine accessibility method [Zhao et al 2010, Duddempudi et al 2013, Date et al 2016]. PCFT has high affinity for folic acid, reduced folates, and anti-folates and has a low pH optimum [Zhao et al 2009, Zhao et al 2011].

Abnormal gene product. Single-nucleotide variants within transmembrane domains, causing amino acid substitutions, result in unstable proteins or proteins with markedly impaired function. Some of the mutated proteins trafficked to the cell membrane and some did not. In three cases (p.Gly147Arg, p.Pro425Arg, p.Arg376Gln) [Mahadeo et al 2010, Zhao et al 2007], mutated isoforms had residual transport activity upon transfection into HeLa cells null for constitutive folate-specific transporters.

References

  • Ahmad I, Mukhtar G, Iqbal J, Ali S W. Hereditary folate malabsorption with extensive intracranial calcification. Indian Pediatr. 2015;52:67–8. [PubMed: 25638192]
  • Atabay B, Turker M, Ozer EA, Mahadeo K, Diop-Bove N, Goldman ID. Mutation of the proton-coupled folate transporter gene (PCFT-SLC46A1) in Turkish siblings with hereditary folate malabsorption. Pediatr Hematol Oncol. 2010;27:614–9. [PMC free article: PMC3885236] [PubMed: 20795774]
  • Borzutzky A, Crompton B, Bergmann AK, Giliani S, Baxi S, Martin M, Neufeld EJ, Notarangelo LD. Reversible severe combined immunodeficiency phenotype secondary to a mutation of the proton-coupled folate transporter. Clin Immunol. 2009;133:287–94. [PMC free article: PMC2783538] [PubMed: 19740703]
  • Corbeel L, Van den Berghe G, Jaeken J, Van Tornout J, Eeckels R. Congenital folate malabsorption. Eur J Pediatr. 1985;143:284–90. [PubMed: 3987728]
  • Date SS, Chen CS, Chen Y, Jansen M. Experimentally optimized threading structure of the proton-coupled folate transporter. FEBS Open Bio. 2016;6:216–30. [PMC free article: PMC4794783] [PubMed: 27047750]
  • Diop-Bove N, Jain M, Scaglia F, Goldman ID. A novel deletion mutation in the proton-coupled folate transporter (PCFT; SLC46A1) in a Nicaraguan child with hereditary folate malabsorption. Gene. 2013;527:673–4. [PMC free article: PMC3836604] [PubMed: 23816405]
  • Duddempudi PK, Goyal R, Date SS, Jansen M. Delineating the extracellular water-accessible surface of the proton-coupled folate transporter. PLoS One. 2013;8:e78301. [PMC free article: PMC3799626] [PubMed: 24205192]
  • Erlacher M, Grunert SC, Cseh A, Steinfeld R, Salzer U, Lausch E, Nosswitz U, Duckers G, Niehues T, Ehl S, Niemeyer CM, Speckmann C. Reversible pancytopenia and immunodeficiency in a patient with hereditary folate malabsorption. Pediatr Blood Cancer. 2015;62:1091–4. [PubMed: 25504888]
  • Geller J, Kronn D, Jayabose S, Sandoval C. Hereditary folate malabsorption: family report and review of the literature. Medicine (Baltimore) 2002;81:51–68. [PubMed: 11807405]
  • Grapp M, Just IA, Linnankivi T, Wolf P, Lucke T, Hausler M, Gartner J, Steinfeld R. Molecular characterization of folate receptor 1 mutations delineates cerebral folate transport deficiency. Brain. 2012;135:2022–31. [PubMed: 22586289]
  • Grapp M, Wrede A, Schweizer M, Huwel S, Galla HJ, Snaidero N, Simons M, Buckers J, Low PS, Urlaub H, Gartner J, Steinfeld R. Choroid plexus transcytosis and exosome shuttling deliver folate into brain parenchyma. Nat Commun. 2013;4:2123. [PubMed: 23828504]
  • Jebnoun S, Kacem S, Mokrani CH, Chabchoub A, Khrouf N, Zittoun J. A family study of congenital malabsorption of folate. J Inherit Metab Dis. 2001;24:749–50. [PubMed: 11804211]
  • Kamen BA, Smith AK. A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev. 2004;56:1085–97. [PubMed: 15094208]
  • Kamen BA, Smith AK, Anderson RGW. The folate receptor works in tandem with a probenecid-sensitive carrier in MA104 cells in vitro. J Clin Invest. 1991;87:1442–9. [PMC free article: PMC295193] [PubMed: 1849150]
  • Kishimoto K, Kobayashi R, Sano H, Suzuki D, Maruoka H, Yasuda K, Chida N, Yamada M, Kobayashi K. Impact of folate therapy on combined immunodeficiency secondary to hereditary folate malabsorption. Clin Immunol. 2014;153:17–22. [PubMed: 24691418]
  • Lanzkowsky P, Erlandson ME, Bezan AI. Isolated defect of folic acid absorption associated with mental retardation and cerebral calcification. Blood. 1969;34:452–65. [PubMed: 4980683]
  • Lasry I, Berman B, Straussberg R, Sofer Y, Bessler H, Sharkia M, Glaser F, Jansen G, Drori S, Assaraf YG. A novel loss of function mutation in the proton-coupled folate transporter from a patient with hereditary folate malabsorption reveals that Arg 113 is crucial for function. Blood. 2008;112:2055–61. [PubMed: 18559978]
  • Mahadeo K, Diop-Bove N, Shin D, Unal E, Teo J, Zhao R, Chang MH, Fulterer A, Romero MF, Goldman ID. Properties of the Arg376 residue of the proton-coupled folate transporter (PCFT-SLC46A1) and a glutamine mutant causing hereditary folate malabsorption. Am J Physiol Cell Physiol. 2010;299:C1153–C1161. [PMC free article: PMC2980313] [PubMed: 20686069]
  • Mahadeo KM, Diop-Bove N, Ramirez SI, Cadilla CL, Rivera E, Martin M, Lerner NB, DiAntonio L, Duva S, Santiago-Borrero PJ, Goldman I D. Prevalence of a loss-of-function mutation in the proton-coupled folate transporter gene (PCFT-SLC46A1) causing hereditary folate malabsorption in Puerto Rico. J Pediatr. 2011;159:623–7.e1. [PMC free article: PMC3935241] [PubMed: 21489556]
  • Malatack JJ, Moran MM, Moughan B. Isolated congenital malabsorption of folic acid in a male infant: insights into treatment and mechanism of defect. Pediatrics. 1999;104:1133–7. [PubMed: 10545560]
  • McIntosh S, Fischer DB, Rothman SG, Rosenfield N, Lobel JS, O'Brien R. Intracranial calcifications in childhood leukemia. an association with systemic chemotherapy. J Pediatr. 1977;91:909–13. [PubMed: 925819]
  • Meyer E, Kurian MA, Pasha S, Trembath RC, Cole T, Maher ER. A novel PCFT gene mutation (p.Cys66LeufsX99) causing hereditary folate malabsorption. Mol Genet Metab. 2010;99:325–8. [PMC free article: PMC2852677] [PubMed: 20005757]
  • Min SH, Oh SY, Karp GI, Poncz M, Zhao R, Goldman ID. The clinical course and genetic defect in the PCFT in a 27-year-old woman with hereditary folate malabsorption. J Pediatr. 2008;153:435–7. [PMC free article: PMC3835188] [PubMed: 18718264]
  • Nakai Y, Inoue K, Abe N, Hatakeyama M, Ohta KY, Otagiri M, Hayashi Y, Yuasa H. Functional characterization of human PCFT/HCP1 heterologously expressed in mammalian cells as a folate transporter. J Pharmacol Exp Ther. 2007;322:469–76. [PubMed: 17475902]
  • Pérez-Dueñas B, Ormazabal A, Toma C, Torrico B, Cormand B, Serrano M, Sierra C, De GE, Marfa MP, Garcia-Cazorla A, Campistol J, Pascual JM, Artuch R. Cerebral folate deficiency syndromes in childhood: clinical, analytical, and etiologic aspects. Arch Neurol. 2011;68:615–21. [PubMed: 21555636]
  • Poncz M, Cohen A. Long-term treatment of congenital folate malabsorption. J Pediatr. 1996;129:948. [PubMed: 8969750]
  • Poncz M, Colman N, Herbert V, Schwartz E, Cohen AR. Therapy of congenital folate malabsorption. J Pediatr. 1981;98:76–9. [PubMed: 6969796]
  • Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, Goldman ID. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell. 2006;127:917–28. [PubMed: 17129779]
  • Qiu A, Min SH, Jansen M, Malhotra U, Tsai E, Cabelof DC, Matherly LH, Zhao R, Akabas MH, Goldman ID. Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction. Am J Physiol Cell Physiol. 2007;293:C1669–C1678. [PubMed: 17898134]
  • Salojin KV, Cabrera RM, Sun W, Chang WC, Lin C, Duncan L, Platt KA, Read R, Vogel P, Liu Q, Finnell RH, Oravecz T. A mouse model of hereditary folate malabsorption: deletion of the PCFT gene leads to systemic folate deficiency. Blood. 2011;117:4895–904. [PubMed: 21346251]
  • Santiago-Borrero PJ, Santini R Jr, Perez-Santiago E, Maldonado N. Congenital isolated defect of folic acid absorption. J Pediatr. 1973;82:450–5. [PubMed: 4540608]
  • Shin DS, Mahadeo K, Min SH, Diop-Bove N, Clayton P, Zhao R, Goldman ID. Identification of novel mutations in the proton-coupled folate transporter (PCFT-SLC46A1) associated with hereditary folate malabsorption. Mol Genet Metab. 2011;103:33–7. [PMC free article: PMC3081934] [PubMed: 21333572]
  • Shin DS, Min SH, Russell L, Zhao R, Fiser A, Goldman ID. Functional roles of aspartate residues of the proton-coupled folate transporter (PCFT; SLC46A1); a D156Y mutation causing hereditary folate malabsorption. Blood. 2010;116:5162–9. [PMC free article: PMC3012536] [PubMed: 20805364]
  • Sofer Y, Harel L, Sharkia M, Amir J, Schoenfeld T, Straussberg R. Neurological manifestations of folate transport defect: case report and review of the literature. J Child Neurol. 2007;22:783–6. [PubMed: 17641272]
  • Steinfeld R, Grapp M, Kraetzner R, Dreha-Kulaczewski S, Helms G, Dechent P, Wevers R, Grosso S, Gartner J. Folate receptor alpha defect causes cerebral folate transport deficiency: a treatable neurodegenerative disorder associated with disturbed myelin metabolism. Am J Hum Genet. 2009;85:354–63. [PMC free article: PMC2771535] [PubMed: 19732866]
  • Steinschneider M, Sherbany A, Pavlakis S, Emerson R, Lovelace R, De Vivo D C. Congenital folate malabsorption: reversible clinical and neurophysiologic abnormalities. Neurology. 1990;40:1315. [PubMed: 2381546]
  • Su PC. Letter: congenital folate deficiency. N Engl J Med. 1976;294:1128. [PubMed: 176588]
  • Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002;302:666–71. [PubMed: 12130730]
  • Toelle SP, Wille D, Schmitt B, Scheer I, Thony B, Plecko B. Sensory stimulus-sensitive drop attacks and basal ganglia calcification: new findings in a patient with FOLR1 deficiency. Epileptic Disord. 2014;16:88–92. [PubMed: 24556562]
  • Torres A, Newton SA, Crompton B, Borzutzky A, Neufeld EJ, Notarangelo L, Berry GT. CSF 5-methyltetrahydrofolate serial monitoring to guide treatment of congenital folate malabsorption due to proton-coupled folate transporter (PCFT) deficiency. JIMD Rep. 2015;24:91–6. [PMC free article: PMC4582027] [PubMed: 26006721]
  • Urbach J, Abrahamov A, Grossowicz N. Congenital isolated folic acid malabsorption. Arch Dis Child. 1987;62:78–80. [PMC free article: PMC1778153] [PubMed: 3813642]
  • Verbeek MM, Blom AM, Wevers RA, Lagerwerf AJ, van de Geer J, Willemsen MA. Technical and biochemical factors affecting cerebrospinal fluid 5-MTHF, biopterin and neopterin concentrations. Mol Genet Metab. 2008;95:127–32. [PubMed: 18722797]
  • Visentin M, Diop-Bove N, Zhao R, Goldman ID. The intestinal absorption of folates. Annu Rev Physiol. 2014;76:251–74. [PMC free article: PMC3982215] [PubMed: 24512081]
  • Wang Q, Li X, Ding Y, Liu Y, Qin Y, Yang Y. The first chinese case report of hereditary folate malabsorption with a novel mutation on SLC46A1. Brain Dev. 2015;37:163–7. [PubMed: 24534056]
  • Wollack JB, Makori B, Ahlawat S, Koneru R, Picinich SC, Smith A, Goldman ID, Qiu A, Cole PD, Glod J, Kamen B. Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model. J Neurochem. 2008;104:1494–503. [PubMed: 18086128]
  • Zhao R, Aluri S, Goldman ID. The proton-coupled folate transporter (PCFT-SLC46A1) and the syndrome of systemic and cerebral folate deficiency of infancy: hereditary folate malabsorption. Mol Aspects Med. 2017;53:57–72. [PMC free article: PMC5253092] [PubMed: 27664775]
  • Zhao R, Diop-Bove N, Goldman ID. Enhanced receptor-mediated endocytosis and cytotoxicity of a folic acid-desacetylvinblastine monohydrazide conjugate in a pemetrexed-resistant cell line lacking folate-specific facilitative carriers but with increased folate receptor expression. Mol Pharmacol. 2014;85:310–21. [PMC free article: PMC3913358] [PubMed: 24249723]
  • Zhao R, Diop-Bove N, Visentin M, Goldman ID. Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr. 2011;31:177–201. [PMC free article: PMC3885234] [PubMed: 21568705]
  • Zhao R, Matherly LH, Goldman ID. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med. 2009;11:e4. [PMC free article: PMC3770294] [PubMed: 19173758]
  • Zhao R, Min SH, Qiu A, Sakaris A, Goldberg GL, Sandoval C, Malatack JJ, Rosenblatt DS, Goldman ID. The spectrum of mutations in the PCFT gene, coding for an intestinal folate transporter, that are the basis for hereditary folate malabsorption. Blood. 2007;110:1147–52. [PMC free article: PMC1939898] [PubMed: 17446347]
  • Zhao R, Unal ES, Shin DS, Goldman ID. Membrane topological analysis of the proton-coupled folate transporter (PCFT-SLC46A1) by the substituted cysteine accessibility method. Biochemistry. 2010;49:2925–31. [PMC free article: PMC2866095] [PubMed: 20225891]

Chapter Notes

Author History

Ndeye Diop-Bove, PhD; Albert Einstein College of Medicine (2010-2017)
I David Goldman, MD (2008-present)
David Kronn, MD (2008-present)
Kris M Mahadeo, MD, MPH; Albert Einstein College of Medicine (2010-2011)
Sang Hee Min, MD; Albert Einstein College of Medicine (2008-2011)
Claudio Sandoval, MD; New York Medical College (2008-2010)

Revision History

  • 27 April 2017 (ma) Comprehensive update posted live
  • 5 June 2014 (me) Comprehensive update posted live
  • 8 December 2011 (me) Comprehensive update posted live
  • 6 May 2010 (me) Comprehensive update posted live
  • 17 June 2008 (me) Review posted live
  • 4 March 2008 (idg) Initial submission
Copyright © 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

Bookshelf ID: NBK1673PMID: 20301716

Views

  • PubReader
  • Print View
  • Cite this Page
  • Disable Glossary Links

Related information

  • MedGen
    Related information in MedGen
  • OMIM
    Related OMIM records
  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed
  • Gene
    Locus Links

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...